Biosimilar And Originator Natalizumab Win English Funding For Highly Active MS

Following Sandoz Launch Of Tyruko Rival To Biogen’s Tysabri

 
• By Neena Brizmohun
  
NHS Written On Wooden Cubes. Symbol Of Healthcare In England
Originator natalizumab and its biosimilar version are to be funded for use via the NHS for certain MS patients (Shutterstock)

More from Biosimilars

More from Products